Login
|
Register
News
Videos
Insights
Peer Exchange
OncNurse TV
Resources
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancers
Supportive Care
Hematology
Prevention
Genetics
Nurse Navigation
Immuno-Oncology
Chemotherapy Safety
Skin Cancer/Melanoma
Contributors
Conferences
Partners
Advocacy
Associations
Schools of Nursing
Publications
CE
Benefits of PARP Inhibitor Use in Breast Cancer
JENNIFER LITTON, MD
Friday, January 11, 2019
Jennifer Litton, MD, Breast Medical Oncologist, MD Anderson Cancer Center, describes how PARP inhibitors compare to standard of care in
breast cancer
treatment.
Discussions >>
Talk about this article with nurses and others in the oncology community in the
General Discussions
Oncology Nursing News discussion group.
Related Videos
Role of the Oral Oncology Nurse
By: Jamie Fritz, RPh
Challenges in Oncology Pharmacy
By: Howard Cohen, RPh, MS, FASHP
Precision Cancer Therapies Program Brings New Hope to Gulf Region
By: Marc Matrana, MD, MS, FACP
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources
Newsroom
Continuing Education
Discussions
Web Exclusives
About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.